Mizuho Securities Reiterates Buy Rating, $57 Price Target on Xencor (XNCR), Sees Upcoming plamotamab Study as Potentially Driving Shares to "Therapeutically-driven Valuation"
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $57.00 price target on Xencor, Inc. (NASDAQ: XNCR).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
